Identification of "Latent Hits" in Compound Screening Collections

Over the past few years, the pharmaceutical industry has relied heavily o­n high-throughput screening (HTS) technology for the identification of hits. Large investments and logistic efforts have been in setting up robotic equipments and in acquiring, assembling, and maintaining big corporate compound collections. However, alongside the established value of HTS as a means for identifying hits from screening collections, it has been widely recognized that the quantity, quality, and diversity of the hits identified have been below original expectations.

For full article Click Here